Under the scanner ; Ranbaxy gets on the wrong side of regulatory bodies.

It's a bitter pill for Indian pharmaceutical giant Ranbaxy. Ithas been hauled over the coals by the United States Food and DrugAdministration (FDA). The FDA has now found serious manufacturingdeficiencies at two of Ranbaxy's plants in India after an inspectionof its facilities. Warning letters have been issued to the company,along with an import alert for the generic drugs manufactured at itsDewas and Paonta Sahib plants. That's not all. The FDA has alsobanned the import of more than 30 generic drugs, includingantibiotics and cholesterol medicines, from the two factories.Though FDA's import alert conceded that there is no evidence ofRanbaxy's medicines being harmful, it added …